Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mateusz T Wasylewski"'
Autor:
Mateusz T Wasylewski, Karolina Strzebonska, Magdalena Koperny, Maciej Polak, Jonathan Kimmelman, Marcin Waligora
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234911 (2020)
ObjectivesDrug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrog
Externí odkaz:
https://doaj.org/article/f7890a9443524ad9b8ed8961926557e2
Autor:
Marcin Waligora, Malgorzata M Bala, Magdalena Koperny, Mateusz T Wasylewski, Karolina Strzebonska, Rafał R Jaeschke, Agnieszka Wozniak, Jan Piasecki, Agnieszka Sliwka, Jerzy W Mitus, Maciej Polak, Dominika Nowis, Dean Fergusson, Jonathan Kimmelman
Publikováno v:
PLoS Medicine, Vol 15, Iss 2, p e1002505 (2018)
BACKGROUND:Pediatric Phase I cancer trials are critical for establishing the safety and dosing of anti-cancer treatments in children. Their implementation, however, must contend with the rarity of many pediatric cancers and limits on allowable risk i
Externí odkaz:
https://doaj.org/article/78717fdf37444366a52d4ee30a8f21ea
Autor:
Karolina Strzebonska, Mateusz Blukacz, Mateusz T. Wasylewski, Maciej Polak, Bishal Gyawali, Marcin Waligora
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-16 (2022)
Abstract Background Umbrella clinical trials in precision oncology are designed to tailor therapies to the specific genetic changes within a tumor. Little is known about the risk/benefit ratio for umbrella clinical trials. The aim of our systematic r
Externí odkaz:
https://doaj.org/article/fde121abb1274be4bdfa675f15665d8f
Autor:
Jakub Stras, Marcin Waligóra, Maciej Polak, Mateusz T. Wasylewski, Bishal Gyawali, Lucja Zaborowska, Karolina Strzebonska, Emilia Slugocka, Mateusz Blukacz
Publikováno v:
Targeted Oncology
Background For research with human participants to be ethical, risk must be in a favorable balance with potential benefits. Little is known about the risk/benefit ratio for pediatric cancer phase II trials testing targeted therapies. Objective Our ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02650ce39d3fe1d715430b8a3e049067
https://doi.org/10.1007/s11523-021-00822-5
https://doi.org/10.1007/s11523-021-00822-5
Autor:
Maciej Polak, Marcin Waligóra, Karolina Strzebonska, Magdalena Koperny, Jonathan Kimmelman, Mateusz T. Wasylewski
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0234911 (2020)
PLoS ONE, Vol 15, Iss 6, p e0234911 (2020)
ObjectivesDrug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0022b4cad1094035ab907f63ad6f240
https://pubmed.ncbi.nlm.nih.gov/32579564
https://pubmed.ncbi.nlm.nih.gov/32579564
Autor:
Mateusz T. Wasylewski, Karolina Strzebonska, Daniel Strech, Nico Riedel, Marcin Waligóra, Lucja Zaborowska, Susanne Wieschowski
Publikováno v:
BMJ Open
ObjectivesTo establish the rates of publication and reporting of results for interventional clinical trials across Polish academic medical centres (AMCs) completed between 2009 and 2013. We aim also to compare the publication and reporting success be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7223836b46da91b90a208bff0515728
https://doi.org/10.1136/bmjopen-2019-034666
https://doi.org/10.1136/bmjopen-2019-034666
Application of either the harm principle or the best interest standard to medical decision making conflicts with some types of pediatric research that pose elevated risk without the reasonable prob...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dc1c978e89a5362157e6a151a589a81
https://ruj.uj.edu.pl/xmlui/handle/item/143768
https://ruj.uj.edu.pl/xmlui/handle/item/143768
